- Home
- RPRX
RPRX
Royalty Pharma plc
as of 02-06-2026 3:46pm EST
$44.60
+$0.74
+1.70%
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Upcoming Earnings Alert:
Get ready for potential market movements as Royalty Pharma plc (RPRX) prepares to release earnings report on 11 Feb 2026.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 16.7B | IPO Year: | 2020 |
| Target Price: | $47.75 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.75 | EPS Growth: | -31.41 |
| 52 Week Low/High: | $29.66 - $44.93 | Next Earning Date: | 02-11-2026 |
| Revenue: | $2,349,844,000 | Revenue Growth: | 3.70% |
| Revenue Growth (this year): | 38.81% | Revenue Growth (next year): | 2.26% |
| P/E Ratio: | 25.49 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered RPRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 74.38%
74.38%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
Coyne Terrance P.
Sell
EVP & CFO
RPRX Feb 4, 2026
Avg Cost/Share
$43.29
Shares
20,163
Total Value
$872,912.73
Owned After
22,885
Coyne Terrance P.
Sell
EVP & CFO
RPRX Feb 3, 2026
Avg Cost/Share
$42.84
Shares
114,954
Total Value
$4,924,996.59
Owned After
22,885
Coyne Terrance P.
Sell
EVP & CFO
RPRX Feb 2, 2026
Avg Cost/Share
$42.08
Shares
108,424
Total Value
$4,562,904.77
Owned After
22,885
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 30, 2026
Avg Cost/Share
$41.09
Shares
20,000
Total Value
$821,810.00
Owned After
0
SEC Form 4
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 23, 2026
Avg Cost/Share
$40.26
Shares
20,000
Total Value
$805,110.00
Owned After
0
SEC Form 4
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 16, 2026
Avg Cost/Share
$39.52
Shares
20,000
Total Value
$790,346.00
Owned After
0
SEC Form 4
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 9, 2026
Avg Cost/Share
$40.78
Shares
20,000
Total Value
$815,634.00
Owned After
0
SEC Form 4
Coyne Terrance P.
Sell
EVP & CFO
RPRX Jan 2, 2026
Avg Cost/Share
$38.42
Shares
69,582
Total Value
$2,673,041.24
Owned After
22,885
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 2, 2026
Avg Cost/Share
$38.48
Shares
20,000
Total Value
$769,650.00
Owned After
0
SEC Form 4
Urist Marshall
Sell
EVP, Research & Investments
RPRX Dec 26, 2025
Avg Cost/Share
$39.32
Shares
20,000
Total Value
$786,380.00
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | RPRX | EVP & CFO | Feb 4, 2026 | Sell | $43.29 | 20,163 | $872,912.73 | 22,885 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Feb 3, 2026 | Sell | $42.84 | 114,954 | $4,924,996.59 | 22,885 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Feb 2, 2026 | Sell | $42.08 | 108,424 | $4,562,904.77 | 22,885 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 30, 2026 | Sell | $41.09 | 20,000 | $821,810.00 | 0 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 23, 2026 | Sell | $40.26 | 20,000 | $805,110.00 | 0 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 16, 2026 | Sell | $39.52 | 20,000 | $790,346.00 | 0 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 9, 2026 | Sell | $40.78 | 20,000 | $815,634.00 | 0 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Jan 2, 2026 | Sell | $38.42 | 69,582 | $2,673,041.24 | 22,885 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 2, 2026 | Sell | $38.48 | 20,000 | $769,650.00 | 0 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Dec 26, 2025 | Sell | $39.32 | 20,000 | $786,380.00 | 0 |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Zacks
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
âž–
AI Sentiment
Neutral
4/10
Zacks
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
âž–
AI Sentiment
Neutral
4/10
Simply Wall St.
Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain
📈
AI Sentiment
Highly Positive
9/10
Compare RPRX vs Leading Stocks
See how RPRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.